Philip joined Karus in 2017 to oversee the translational research programmes associated with Karus’ clinical trials. Since April 2020, Philip has also directed Karus’ R&D programme.
Philip is a physician scientist and precision oncology specialist who has held diverse roles across the healthcare, academic and commercial sectors. He is a qualified haematologist and has worked close to 20 years in the NHS as a front-line physician and pathologist. In addition, he spent 8 years in academic research, working with molecular, cellular and whole-organism models of cancer in Cambridge and Vancouver. Current projects encompass oncology drug development, design of genomic biomarker assays and support for biomarker stratified clinical trials. The uniting theme of this work is the use of biomarkers to accelerate drug development and ensure that patients receive the most appropriate therapies. These projects are underpinned by a portfolio of academic research focused on cancer biology and genomics, through honorary positions at the University of York, Sanger Institute, and Mayo Clinic, USA.